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Abstract Pulmonary infections caused by Aspergillus
species are associated with significant morbidity and
mortality in immunocompromised patients. Although the
treatment of pulmonary fungal infections requires the use of
systemic agents, aerosolized delivery is an attractive option
in prevention because the drug can concentrate locally at
the site of infection with minimal systemic exposure.
Current clinical evidence for the use of aerosolized delivery
in preventing fungal infections is limited to amphotericin B
products, although itraconazole, voriconazole, and caspo-
fungin are under investigation. Based on conflicting results
from clinical trials that evaluated various amphotericin B
formulations, the routine use of aerosolized delivery cannot
be recommended. Further research with well-designed
clinical trials is necessary to elucidate the therapeutic role
and risks associated with aerosolized delivery of antifungal
agents. This article provides an overview of aerosolized
delivery systems, the intrapulmonary pharmacokinetic
properties of aerosolized antifungal agents, and key find-
ings from clinical studies.
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Introduction
Pulmonary infections caused by Aspergillus species are
associated with significant morbidity and mortality in
immunocompromised patients [1•]. Poor lung function
coupled with immune suppression resulting from bone
marrow or solid-organ transplantation can predispose patients
to infections caused by Aspergillus [2]. In fact, approximately
20% to 25% of bone marrow or lung transplant recipients
develop invasive pulmonary aspergillosis [2, 3].
Treatment of pulmonary fungal infections requires the
use of systemic agents because there is a lack of data on
aerosolized administration. However, aerosolized delivery
of antifungal agents has been evaluated for prevention of
invasive pulmonary aspergillosis. Aerosolized delivery is
an attractive option, as high local drug concentrations are
achieved with minimal systemic exposure, which is
especially crucial owing to the adverse effects associated
with systemic administration of some antifungal agents.
Although aerosolization has been proposed for decades,
data on the pulmonary pharmacokinetics, safety, and
efficacy of antimicrobial agents administered by this
method remain insufficient. Furthermore, drug products
that are formulated exclusively for the purpose of aerosol-
ization are limited.
Aerosolized Delivery Systems
An effective antimicrobial regimen optimizes the eradica-
tion of pathogenic organisms by achieving drug concen-
trations sufficient to yield maximum effect at the site of
infection. Aerosolized administration delivers drug directly
to the respiratory system to allow concentration of the
antimicrobial agents at the site of infection and, equally
J. Le (*)
UCSD Skaggs School of Pharmacy and Pharmaceutical Sciences,
9500 Gilman Drive MC 0714,
La Jolla, CA 92093-0714, USA
e-mail: jenle@ucsd.edu
D. S. Schiller
Saint Barnabas Medical Center,
94 Old Short Hills Rd,
Livingston, NJ 07039, USA
Curr Fungal Infect Rep (2010) 4:96–102
DOI 10.1007/s12281-010-0011-0
important, reduces systemic exposure. As a result, aerosol-
ized administration of anti-infective agents maximizes
efficacy and limits toxicities associated with the specific
agents, making it an appealing option [4–7].
Drug administration by aerosol requires nebulization,
which is the primary mode for pulmonary delivery of
antimicrobial agents. Many different configurations exist
for nebulization; the three main types are jet systems,
ultrasonic systems, and systems that use a vibrating mesh/
aperture plate [8•]. The type of nebulizer system can
influence drug deposition into the airways, but optimal
drug deposition, particularly deep in the respiratory tract,
requires proper administration technique regardless of the
system used [9]. Recommendations are available for
aerosolized drug delivery in spontaneously breathing and
mechanically ventilated patients [10, 11].
The physical properties of antimicrobial formulations (eg,
size, viscosity, surface tension, osmolality, tonicity, and pH)
will affect the degree of pulmonary penetration. One of the
most important factors determining deposition into the small
airways and alveoli is the particle size or mean mass
aerodynamic diameter (MMAD). The MMAD of a particle
is the diameter of the sphere with unit density that settles at the
same rate as the particle. The optimal particle size for aerosol
drug delivery is 1 to 5 micrometers (µm). Particles that are
1 µm or less are likely to be eliminated during exhalation,
whereas particles that are 5 µm or greater are deposited into
the oropharynx and swallowed [12]. Akin to particle size,
viscosity also contributes to the efficiency of drug delivery.
In fact, viscosity is inversely proportional to the rate of
aerosolization. Viscosity greater than 1.5 centipoises dramat-
ically decreases the rate of aerosolization [13].
Whereas some characteristics of aerosolized particles
determine the depth of deposition and rate of aerosolization,
other characteristics determine the observed toxicities, such
as cough, which is a common adverse effect of aerosolized
delivery. Physical properties of antimicrobial formulations,
including osmolality, tonicity, pH, and surface tension, can
greatly influence the occurrence of cough. Induction of
cough can occur when the osmolality is less than
100 mOsm/kg or when it exceeds 1,100 mOsm/kg. Because
aerosolized solutions are generally produced from intrave-
nous formulations that contain preservatives (eg, phenols
and bisulfites), these solutions are often hypertonic, with
unadjusted pH values. These preservatives may contribute
to cough, airway irritation, and bronchoconstriction. Sur-
face tension of drug particles also may contribute to cough.
Jet Nebulizers
Although three main nebulizer systems are available, the most
commonly used system for aerosolization of antifungal agents
is the jet nebulizer. Two types of jet nebulizer systems are
currently used in clinical practice: standard and breath-
enhanced. The breath-enhanced nebulizer system demon-
strates better drug delivery than the standard system, as 10%
to 20% of the patient’s inspiration must pass the nebulization
chamber for aerosol generation; it is also associated with
fewer quality control problems [14]. The optimal particle size
for medications delivered via jet nebulizer systems ranges
between 1 and 5 µm, allowing for drug deposition into the
smaller airways (usually 1–2 µm or smaller for parenchymal
deposition) [15]. A drug solution volume of 4 to 6 mL and
flow rate of 8 L/min is recommended for jet nebulizers [16].
Some drug loss may occur, as residual (“dead”) volumes of 1
to 3 mL fail to be nebulized.
To optimize delivery of the jet nebulizer system and
minimize the residual volume, a cone-shaped nebulizer
should be used. Improving the wetness of plastic surfaces
and reducing the internal surface area of the nebulizer will
also improve delivery. In contrast, humidity increases
aerosol loss and may consequently decrease drug delivery
by 40% [13, 17]. More drug delivery occurs late in the
nebulization process because of evaporative loss of water
from the drug solution. Advances in jet nebulizer systems
are on the horizon, with attempts to decrease the loss of
drug during exhalation and to limit environmental release
of drug aerosols by using filters or one-way valves [15].
The main advantages of jet nebulizers are that they are
inexpensive, disposable, and do not require special equip-
ment. Microbial growth in improperly cleaned nebulizers is
eliminated with disposable nebulizers. Some disadvantages
are that power sources, equipment setup, and some cleaning
for equipment maintenance are required. Notably, there are
significant variations in performance of various nebulizers
within the same brand and across different brands [16].
Therefore, they should not be used interchangeably when
precise dosing is required for therapeutic response.
Aerosolized Antifungal Agents
Amphotericin B Products
Amphotericin B has broad activity against various yeasts,
molds, and dimorphic fungi, including Aspergillus species.
Its poor systemic distribution to the lungs results in the
need for higher doses, which may place patients at
increased risk for adverse drug reactions [18–20]. Further-
more, because amphotericin B exhibits concentration-
dependent pharmacodynamics, optimal fungicidal activity
relies on attainment of high drug concentrations—that is, a
high ratio of maximum concentration (Cmax) to the
minimum inhibitory concentration (MIC) [21]. Poor drug
solubility following parenteral administration hampers this
fungicidal activity of amphotericin B. Therefore, an
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aerosolized formulation of amphotericin B may allow a
lower dose to be used while maintaining high lung
concentrations in patients with pulmonary fungal infections.
The unique particle structure and size of each amphotericin
B product is inversely related to the aerosolized particle size.
To achieve aerosolization, the large molecules of the various
intravenous amphotericin B formulations—deoxycholate
(AmBd), liposomal (L-AmB), colloid dispersion (ABCD),
and lipid complex (ABLC)—result in small aerosolized
particle sizes with MMAD ranging from 0.90 to 2.43 µm
[22]. The variable sizes of these different aerosolized
amphotericin B formulations influence the extent of alveolar
distribution and half-life of the drug in the lungs [22–25].
The intrapulmonary pharmacokinetic properties of aero-
solized amphotericin B have been evaluated using different
doses and formulations of amphotericin B, as well as
different types of nebulizers [3, 23, 26]. One study that
evaluated the distribution of nebulized AmBd (6 mg) in 17
lung transplant recipients demonstrated preferential deposi-
tion in the allografted lung and a greater accumulation in
the distal zones of the bronchial tree [3]. In addition, the use
of RespirGard II (Marquest; Englewood, CO) and PariBoy
or Pari IS II (both Pari Werke; Starnberg, Germany) for
nebulization of AmBd has been shown to generate particles
that deposit in the alveoli, trachea, and nasopharynx [27].
Based on a pharmacokinetic study in sheep, the maximum
intrapulmonary concentration was not influenced by the
dose (5 mg vs 30 mg) [28]. However, the area under the
concentration-time curve was greater for the larger dose.
Another pulmonary distribution study evaluated 35 mg
ABLC over 30 min using a breath-actuated jet nebulizer (N=
12) [26]. In contrast to AmBd, there was no significant
difference in the amount of ABLC deposited between native
and allografted lungs (3.9 mg vs 2.1 mg, P=0.2) in recipients
of single lung transplants. However, a slightly larger dose
was delivered to the right lung versus the left lung (4.0 mg
vs 2.8 mg, P=0.06) in recipients of double lung transplants.
Nebulized L-AmB has been shown to exhibit biexpo-
nential kinetics with an elimination half-life of 22 days for
neutral liposomes in an animal model [29]. This half-life
offers an advantage over aerosolized AmBd, which has a
half-life of 4.8 days [30]. In addition, the long half-life for
L-AmB has been correlated with prolonged antifungal
activity lasting up to 6 weeks [22]. A more recent study
on tolerability in humans suggested that administration of
L-AmB as infrequently as every 2 weeks may be adequate
to prevent aspergillosis [31]. If true, this regimen may
significantly improve patient compliance.
Investigational Agents
Several antifungal products specifically formulated for
aerosolization are in various stages of development. An
amphotericin B formulation containing liposomes coated
with macrophage-specific ligands (O-palmitoyl mannan or
O-palmitoyl pullulan) was created to augment selective
presentation to alveolar macrophages [32]. Although
studied only in a rat model, this formulation demonstrated
higher localization and retention in lungs than aerosolized
plain AmBd solution (three times more after 6 h). However,
there was considerable systemic absorption (20% to 50%)
with this new formulation.
Itraconazole has also been studied for aerosolization.
Using a new nanotechnology technique that spray-freezes a
drug with poor water solubility into a liquid, the effective-
ness of aerosolized itraconazole as a prophylactic agent
against invasive pulmonary aspergillosis caused by Asper-
gillus flavus and Aspergillus fumigatus has been studied in
immunocompromised mice [33, 34]. Single and multiple
aerosolized dose studies in mice have demonstrated the
ability to achieve therapeutic pulmonary concentrations
within 60 min after completion of nebulization while
maintaining serum levels 25 to 50 times lower [35, 36].
Although results appear promising in mice, further studies
are needed before extrapolating them to the clinical setting.
Despite its good distribution into the lungs, the intrave-
nous formulation of voriconazole has been studied for
aerosolization at quite low doses [37]. Therapeutic drug
levels in human lung tissue occurred 30 min after inhalation
of a 10 mg/mL solution [38]. Maximal pulmonary concen-
trations were 1.4 times higher than plasma concentrations,
perhaps on account of the low potential for pulmonary
metabolism and the high distribution across lung mucosal
surfaces.
Pneumocandin, an older derivative of caspofungin, has
been shown to be effective in delaying mortality for
prophylaxis against invasive pulmonary aspergillosis in rats
[39]. Aerosolization of caspofungin is currently being
evaluated using three different jet nebulizer and compressor
systems. The ability to achieve favorable physiochemical
properties for nebulization requires dilution in normal
saline and a more concentrated (30 mg/mL) solution.
Further in vivo studies are needed to elucidate the role of
aerosolized caspofungin [40].
Human Studies: Prophylaxis
Clinical experience with aerosolized antifungal agents is
limited to various formulations of amphotericin B products,
although itraconazole and caspofungin are currently under
investigation. Amphotericin B has been the most studied
aerosolized antifungal agent for prophylaxis against inva-
sive aspergillosis in patients with hematologic malignancies
and lung transplantation. Its use as an alternative agent for
the treatment of invasive aspergillosis has been limited to
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case reports rather than clinical studies [41, 42]. Therefore,
only clinical studies for prophylaxis against invasive
aspergillosis are reviewed in this section.
Hematologic Malignancies
Two groups of investigators performed dose-finding studies
for aerosolized AmBd in neutropenic patients with hema-
tologic malignancies. One observational study in stem cell
transplant recipients (n=18) and leukemia patients (n=8)
demonstrated that invasive aspergillosis was not observed
with 5 to 20 mg of AmBd nebulized twice daily [5].
Prophylactic treatment was continued for the duration of
neutropenia or until intravenous antifungal therapy was
initiated. Notably, 14 (54%) of the patients required a
switch to intravenous AmBd for fevers. None of the
patients developed clinically suspicious or pathologically
documented invasive aspergillosis. No adverse effects were
reported with the use of nebulized AmBd.
Another dose-finding study in granulocytopenic patients
with hematologic malignancies (N=42) showed the effec-
tiveness of AmBd (5–10 mg) nebulized three times daily in
preventing invasive fungal infections [43]. Though 88% of
patients tolerated the regimen of 5 mg three times daily,
only 48% tolerated a dose escalation up to 10 mg three
times per day. Common adverse effects reported were mild
cough and dyspnea, which occurred in 19% of patients.
Invasive fungal infections developed in 28% of patients;
there was no difference between any of the dosing regimens
in the occurrence of fungal infections.
The largest randomized, unblinded, placebo-controlled,
multicenter trial evaluated the effectiveness of inhaled
AmBd in neutropenic patients (N=382) with hematologic
malignancies, including leukemias, non-Hodgkin’s lympho-
ma, or solid tumors requiring high-dose chemotherapy with
autologous bone marrow transplantation [6]. The prelimi-
nary results of this study were published previously [44].
Patients were randomized to receive nebulized AmBd or no
prophylaxis (including inhalational, oral, and parenteral
routes) until resolution of neutropenia (median 27 days;
range 2–50). Notably, no significant differences were
detected in the development of invasive aspergillosis (4%
vs 7%, P=0.37) and infection-related mortality (8% vs 7%,
P=0.79) between those who received nebulized AmBd and
placebo. Cough, bad taste, and nausea were the most
commonly reported adverse effects in patients who received
inhalation prophylaxis.
Safety and efficacy data with lipid formulations of
amphotericin B in neutropenic patients with hematologic
malignancies are more promising. In a prospective, open-
label, noncomparative study, the safety and tolerability of
aerosolized ABLC was evaluated in 40 recipients of
allogeneic hematopoietic stem cell transplants [45]. Sub-
jects received fluconazole concurrently with aerosolized
ABLC treatment once daily for 4 days, then once weekly
for 13 weeks. Overall, aerosolized ABLC was well
tolerated, with reports of cough, nausea, taste disturbance,
or vomiting in 2% of 458 total treatments. Although 5% of
treatments resulted in reduced pulmonary function measure-
ments, no patients required bronchodilators or withdrawal
from the study. Although no participants developed
invasive aspergillosis, three developed other invasive
fungal infections, which were caused by Fusarium species,
Zygomycetes, and Candida glabrata.
A recent randomized, placebo-controlled trial of L-AmB
(12.5 mg nebulized twice weekly on consecutive days) was
conducted in 271 patients with hematologic diseases who
had expected neutropenia for at least 10 days; 139 patients
received L-AmB and 132 received placebo [46••]. This
study demonstrated a significant reduction in the incidence
of invasive pulmonary aspergillosis with the aerosolized
antifungal L-AmB (OR, 0.26; 95% CI, 0.09–0.72; P=0.05
using intent-to-treat analysis). However, cough occurred in
16 patients in the treatment group versus only 1 in the
placebo group (P=0.002). Although no serious drug-related
adverse events were reported, more patients in the treatment
group discontinued therapy (45% vs 30% in the placebo
group; P=0.01) because of weakness, technical problems
with aerosolized delivery, and cough. Increase in serum
creatinine was not observed in the treated patients.
Lung Transplantation
Amphotericin B via nebulization has also been evaluated in
patients who received immunosuppressive medications
following solid-organ transplantation (primarily lung trans-
plants). One prospective, nonrandomized, uncontrolled
study evaluated the effectiveness of prophylactic use of
AmBd in 55 lung transplant recipients [47]. Patients
received AmBd (30 mg nebulized three times daily) for
120 days after transplantation, then 30 mg daily for life.
Using a multivariate analysis, the risk of developing
aspergillosis was decreased with nebulized AmBd (OR,
0.13; 95% CI, 0.02–0.69; P<0.05). A few patients
experienced mild adverse effects, but only one patient
withdrew from the study, because of bronchospasm.
In a retrospective review of lung transplant recipients,
oral voriconazole (n=65) was compared with oral flucona-
zole with or without inhaled AmBd (n=30) [48]. Itracona-
zole was substituted for fluconazole in patients colonized
with Aspergillus (n=15). The rate of proven or probable
invasive aspergillosis was significantly less in the vorico-
nazole group than in the fluconazole/itraconazole group
(2% vs 23%, P=0.001). Although the authors did not report
the outcomes for patients who received inhaled AmBd, it
was evident that voriconazole was superior despite the
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presence of Aspergillus colonization in patients who
received itraconazole with or without inhaled AmBd.
Results from this review suggest that further data are
needed to support the use of aerosolized antifungals in this
population in light of the advent of mold-active azole
antifungals, which are more easily administered than
traditional agents.
In addition to AmBd, ABLC also has been evaluated in
three clinical studies, one of which was a trial comparing
AmBd and ABLC. In a prospective, noncomparative study
designed to evaluate safety, aerosolized ABLC was subjec-
tively well tolerated in 98% of 51 recipients of lung or
heart-lung transplants [49]. No significant drug-related
adverse events were reported. In another study, which
retrospectively evaluated the effectiveness of ABLC nebu-
lization, invasive fungal infections occurred in 2% of 60
lung transplant recipients [50]. Patients received ABLC
(50 mg nebulized once every 2 days for 2 weeks) with oral
fluconazole (200 mg every 12 h). Nausea and vomiting
were reported in four patients.
A randomized, double-blind study compared two differ-
ent formulations of aerosolized amphotericin B for the
prevention of fungal infections in recipients of lung and
heart-lung transplants [4]. In addition to bronchodilator
treatment, patients received nebulized AmBd (25 mg daily)
(n=49) or ABLC (50 mg daily) (n=51) for 4 days, then
weekly for 7 weeks following transplantation. The doses
were doubled for patients on mechanical ventilation. No
significant difference in the development of invasive fungal
infection was detected between the study groups within
2 months after treatment initiation (14% infection with
AmBd vs 12% with ABLC). Notably, experiences of
adverse events were more likely to occur with AmBd
(OR, 2.16; 95% CI, 1.10–4.24; P=0.02).
Summary: Should Nebulized Amphotericin B Be Used
for Prophylaxis?
Some evidence exists for prophylactic use of aerosolized
amphotericin B formulations, including AmBd (20–25 mg
once daily), ABLC (50 mg once daily), and L-AmB
(12.5 mg twice weekly on 2 consecutive days), against
invasive aspergillosis in non-mechanically ventilated
patients with hematologic malignancies or lung transplan-
tation. For patients on mechanical ventilation, the doses of
AmBd and ABLC should be doubled. The lipid-based
formulations, including L-AmB, appear to have favorable
safety and pharmacokinetic profiles. Overall, few well-
designed, randomized, controlled trials have assessed their
efficacy. Based on clinical studies, which produced
conflicting results, and consistent with a recommendation
from the Infectious Diseases Society of America, routine
use of nebulized amphotericin B cannot be recommended
[1•]. More clinical evidence is necessary, particularly
regarding the prevention of aspergillosis in lung transplant
recipients.
Safety of Aerosolized Antifungals
One major advantage of aerosolized administration of
antimicrobial agents is the reduction of systemic circula-
tion—a benefit particularly valuable for amphotericin B,
which may be nephrotoxic. Nonetheless, toxicities, includ-
ing the theoretical risk of systemic effects, may still occur
with aerosolized administration. With the current dearth of
safety and tolerability data, caution should be used when
employing aerosolized delivery of anti-infective agents.
Caution is particularly important when special formulations
for aerosolization are unavailable, as illustrated by two
fatalities surrounding the nebulization of colistimethate and
zanamivir inhalation powder, incidents that prompted the
US Food and Drug Administration to issue an alert to
clinicians [51] and a MedWatch safety report [52] respec-
tively. These deaths were attributed to pulmonary injury
resulting from increased colistin concentrations caused by
prolonged storage (longer than 24 h) of the premixed
colistimethate solution, and to obstruction of the ventilator
created by lactose contained in the zanamivir nebulizing
solution.
The intensity of adverse effects associated with the use
of aerosolized amphotericin B (including the liposomal
formulations) ranges from mild to severe and may occur
with limited exposure, such as once-weekly dosing [53••].
The most common adverse events are local pulmonary
effects including cough, decline in pulmonary function
tests, and chest tightness [54, 55]. Cough may occur with
all aerosolized amphotericin B formulations, including
AmBd, ABLC, and L-AmB [6, 45, 55]. In addition,
decreases in both the forced expiratory volume and forced
vital capacity may occur with aerosolized ABLC [45]. Most
of these side effects are mild and result in nominal drug
discontinuations. However, bronchoconstriction was
reported in one patient who received nebulized AmBd
[47]. The administration of a bronchodilator within 15 min
before use of the aerosolized antimicrobial may prevent
bronchospasm, especially in smokers and asthmatics [56].
Other adverse effects reported with the nebulization of
amphotericin B include nausea, vomiting, taste disturban-
ces, tongue numbness, and exacerbation of heart failure
[50, 53••]. Though data from the majority of experiences
report no systemic exposure, there are reports of trace
amounts of amphotericin B in the serum following aerosol
administration [31, 54]. Nonetheless, the main adverse
events are pulmonary, and the clinical relevance of drug
detection in the serum remains unknown.
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Several studies have compared safety outcomes between
the different formulations of amphotericin B. More adverse
events have been reported with AmBd than with ABLC,
although these have not significantly increased the need for
drug discontinuation [4]. Comparable adverse events were
reported in similar proportions of patients receiving AmBd
and L-AmB [54]. AmBd may have a detrimental effect on
pulmonary surfactant function, possibly resulting from the
detergent effect of the deoxycholate rather than as a direct
effect of the amphotericin [25]. This effect has not been
evident with the lipid formulations.
Conclusions
Current clinical evidence for the use of aerosolized delivery
is limited to amphotericin B products for prophylaxis
against invasive pulmonary aspergillosis in patients with
hematologic malignancies or lung transplantation. Based on
conflicting results from clinical trials on efficacy and a lack
of safety data, the routine use of aerosolized delivery
cannot be recommended. Further research with well-
designed clinical trials is necessary to elucidate the
therapeutic role of aerosolized delivery of antifungal agents,
as well as the associated risks.
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